Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series

BRAFV600E is the driver mutation for approximately 10% of colorectal cancers and is found more often in right-sided disease and older patients.1-3 The presence of this mutation is associated with a poor prognosis and resistance to chemotherapy, especially in the metastatic setting.4-6 Standard first line therapy in these patients has a significantly shorter overall survival compared to patients with BRAF wild-type disease.7,8 Historically, subsequent lines of chemotherapy have shown limited efficacy with median progression free survival (PFS) of 2 to 3 months and overall survival (OS) of around 4 to 6 months.